Literature DB >> 18176660

Neural network dysfunction in Alzheimer's disease: a drug development perspective.

David H Small1.   

Abstract

Over the last few years, a major focus of Alzheimer's disease research has been to understand the mechanisms by which build-up of the beta-amyloid protein (Abeta) in the brain leads to chronic neurodegeneration and eventual cell death. It is increasingly recognized that cell death is not a major cause of dementia. Indeed, recent studies suggest that Abeta causes neuritic dystrophy and interferes with mechanisms of synaptic plasticity such as long-term potentiation. There are also a number of well-described homeostatic mechanisms in the brain that help to maintain signal strength as a consequence of lowered synaptic input, which may occur as a consequence of neuritic dystrophy. This review examines mechanisms of synaptic scaling in the brain and explores prospects for future drug development based on a neural network perspective. Copyright 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Year:  2007        PMID: 18176660     DOI: 10.1358/dnp.2007.20.9.1162245

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  3 in total

Review 1.  Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.

Authors:  Peter Csermely; Tamás Korcsmáros; Huba J M Kiss; Gábor London; Ruth Nussinov
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 2.  Long-lasting changes in neural networks to compensate for altered nicotinic input.

Authors:  Danielle John; Darwin K Berg
Journal:  Biochem Pharmacol       Date:  2015-07-20       Impact factor: 5.858

3.  Cholinergic Synaptic Homeostasis Is Tuned by an NFAT-Mediated α7 nAChR-Kv4/Shal Coupled Regulatory System.

Authors:  Abdunaser Eadaim; Eu-Teum Hahm; Elizabeth D Justice; Susan Tsunoda
Journal:  Cell Rep       Date:  2020-09-08       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.